NCT07106749
- Conditions
- Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia/Lymphoma, Burkitt Lymphoma, +20 more
- Locations
-
- Institute of Hematology & Blood Diseases Hospital Tianjin, Tianjin Municipality, China
Clinical trial condition
Lymphoma, B-Cell
Explore clinical trials studying Lymphoma, B-Cell. Study availability and eligibility vary by location and protocol.
1,618 public trials
340 recruiting studies
Lymphoma, B-Cell trial results
NCT06651853
- Conditions
- Diffuse Large B-cell Lymphoma, Disease Attributes, Hemic and Lymphatic Diseases, +14 more
- Locations
-
- The First Affiliated Hospital of Xiamen University Xiamen, Fujian, China
NCT07072208
- Conditions
- Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
- Locations
-
- The First Affiliated Hospital of Soochow University Suzhou, Jiangsu, China
NCT07070648
- Conditions
- DLBCL, Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, +10 more
- Locations
-
- Fudan University Shanghai Cancer Center Shanghai, Shanghai Municipality, China
NCT06682130
- Conditions
- Diffuse Large B-cell Lymphoma(DLBCL), Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
- Locations
-
- The First Affiliated Hospital of Soochow University Suzhou, Jiangsu, China
NCT00935090
- Conditions
- Amyloidosis, Blast Crisis, Blood Coagulation Disorders, +101 more
- Locations
-
- Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States
NCT06785324
- Conditions
- B Cell Acute Lymphoblastic Leukemia (B-ALL), B-ALL, Burkitt Lymphoma, +17 more
- Locations
-
- University of Chicago Medicine Comprehensive Cancer Center Chicago, Illinois, United States
- Conditions
- Diffuse Large B-cell Lymphoma, Disease Attributes, Hemic and Lymphatic Diseases, +13 more
- Locations
-
- Fudan University Shanghai Cancer Center Shanghai, Shanghai Municipality, China
NCT06700798
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- The First Affiliated Hospital of Nanchang University Nanchang, Jiangxi, China
Recruiting
Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma
NCT07022223
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- Second Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou, Zhejiang, China
- Dongyang People's Hospital Dongyang, China
- Affiliated Hangzhou First People's Hospital Hangzhou, China
- Zhejiang cancer Hospital Hangzhou, China